Brcaone 150mg Tablet

Brcaone 150mg tablet Is used in the treatment of breast and ovarian cancer in women. Its salt formation is Olaparib as an active ingredient and belongs to the class of PARP inhibitor. It work by inhibiting the PARP enzyme, preventing cancer cells from repairing damaged DNA, which leads to their death and help slow the progression of the disease. Doctors do not prescribe this medication to adults under the age of 18. Doctor's prescription is required while starting or adjusting the dose, as proper guidance is essential to ensure safety and effectiveness of the treatment.

Breast cancer and ovarian cancer

Brcaone 150mg tablet also show various side effects which are acute or chronic as well. Some patients may resolve on their own but some need proper medical attention to cure the disease. Visit the doctor if these symptoms may persist or worsen at the time of treatment:
● Muscle cramps
● Confusion, visual disturbances, seizures, and headache
● Breathlessness
● Swelling of feet
● Changes in heartbeat
● High blood pressure
● Pneumonia
● Loss of appetite
● Sensitivity, tingling and burning sensation of the skin
● Nausea, vomiting, and diarrhea
● Mouth ulcers
● Constipation

The correct dosage and duration of Brcaone 150mg tablet is recommended by the healthcare professional. Doctors prescribed this medication with or without food based on patient response to the treatment. Do not self administered, follow the recommended dosage as prescribed by the doctor to ensure safe and effective treatment option.

Brcaone 150mg tablet is a targeted therapy which contains PARP (inhibitor that works by the blocking PARP enzyme to stop cancer cell from repairing their DNA, leading to cell death. The medication slowly stops the progression of the disease and helps prevent the spread or further growth of cancer in the body.

• Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018). Olaparib for the treatment of breast cancer. Expert review of anticancer therapy, 18(6), 519-530.
• Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., ... & Domchek, S. M. (2015). Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. Journal of clinical oncology, 33(3), 244-250.
• Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., ... & Domchek, S. M. (2015). Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. Journal of clinical oncology, 33(3), 244-250.
• Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., ... & Carmichael, J. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.
• Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., ... & Saad, F. (2022). Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM evidence, 1(9), EVIDoa2200043.